Retinal Vein Occlusion

Overview of branch retinal vein occlusion and central retinal vein occlusion.

What is a Retinal Vein Occlusion?

Arteries bring blood to the eye and veins bring blood back to the heart. While arteries have tough walls which usually become harder with age, veins have thin walls which remain pliant and soft throughout life. Because of the anatomy of the eye, the retinal veins are prone to occlusion. There are two main locations where retinal veins are occluded. One is at the crossing of a retinal arteriole and branch retinal vein. An occlusion at a crossing of a branch retinal arteriole and branch retinal vein causes a branch retinal vein occlusion. The second is at the main trunk of the retinal vein where it leaves the eye through the optic nerve. An occlusion at the main trunk of the retinal vein causes a central retinal vein occlusion. The picture shows a photo with dilated veins and retinal hemorrhages from a fresh central retinal vein occlusion.

What is a Branch Retinal Vein Occlusion?

A branch retinal vein occlusion occurs when, because of hardening of the arteries, a branch retinal artery compresses a branch retinal vein causing blockage of the vein and decreased circulation in the distribution of that branch retinal vein. (see image) [note: the branch arteries are really arteriols and the branch veins are really veinules] There are several possible treatments for branch retinal vein occlusion including intravitreal injections, laser, and even surgery. Patients with BRVO lose vision for several reasons: poor circulation, hemorrhage and macular edema (swelling). There is no treatment, at the moment, to increase circulation or to remove hemorrhage. The macular edema, however, does respond well to intravitreal injections with Lucentis, Avastin, or steroids.

Read more

What is a Central Retinal Vein Occlusion?

The inner layers of the retina receive their blood supply from the central retinal artery. The blood returns to the heart through the central retinal vein. Both vessels enter the eye through a small opening in the middle of the optic nerve. Either because this opening shrinks or because the artery hardens or because of circulations problems, the central retinal vein can become partially or completely occluded. When a patient develops a central retinal vein occlusion (CRVO), they lose some or most of their central vision. The retinal veins dilate and their are retinal hemorrhages. Patients often develop swelling of the central retina-cystoid macular edema--causing some of the vision loss. Without treatments, 25% of eyes improve, 50% stabilize, and 25% worsen. Monthly examinations of pateints with CRVO for less than six months are very important. Some patients with CRVO and very bad circulation, develop a severe type of glaucoma. In this situation, the eye becomes red and painful and without treatment, total visual loss can occur rapidly. If an examining doctor sees early signs that this complication may occur, then laser treatment can sometimes protect the eye. Once the pressure rise occurs, surgery can be helpful.

Read more

Retinal Vein Occlusion NEWS

Below are current articles from a Google News Feed on Retinal Vein Occlusion

Worldwide Retinal Vein Occlusion Market Size by Market Opportunities, Type, Product, Application & Characteristics  The Spring Times

Retinal Vein Occlusion Market report covers the disease overview, definition, classification, symptoms, ethology, pathophysiology and diagnostic methods.

Effect of intravitreal aflibercept on corneal endothelial cells: a 6-m | OPTH  Dove Medical Press

Effect of intravitreal aflibercept on corneal endothelial cells: a 6-month follow-up study.

Global Retinal Vein Occlusion Treatment Market 2019-2023: Competitor Analysis, Growth, Shares, Manufacturers, Trends and Applications  DD News Herald

Latest Global Retinal Vein Occlusion Treatment Market share analysis for the top industry players & new entrants, regional and country level segments, ...

India- Retinal Vein Occlusion Market 2019 Global Forecasts Analysis, Company Profiles, Competitive Landscape and Key Regions 2023 Available at Market Research Future  MENAFN.COM

(MENAFN - GetNews) Market Research Future has starting late imparted another examination to its wide research portfolio, which is titled as 'Retinal Vein ...

Global Retinal Vein Occlusion Treatment Market 2019: Analysis, Production, Size, Consumption, Scope Forecast to 2023  DD News Herald

Retinal Vein Occlusion Treatment Market Report delivers a detailed study with present and upcoming opportunities, manufacturers, regional analysis, ...

Global Retinal Vein Occlusion Therapeutics Market 2019: Growth Factors Details and Competitive Analysis 2025  Honest Version

Global Retinal Vein Occlusion Therapeutics Market Report allows a reader to obtain an absolute evaluation of each influential factor involved in the Global ...

Protective effects of ADM-RAMP2 system make it a new therapeutic target for retinal vein occlusion  EurekAlert

Philadelphia, January 15, 2019 - A clot in the retinal vein can lead to severe and irreversible loss of vision. In a report in the American Journal of Pathology ...

Retinal Vein Occlusion Market 2019 Research Report  reportsherald.com

Global Retinal Vein Occlusion Market – Epidemiology Forecast to 2028 report delivers an in-depth understanding of the disease, historical & forecasted ...

ADM-RAMP2 system could be therapeutic target for retinal vein occlusion  Drug Target Review

Researchers suggest that the retinoprotectivity of the ADM-RAMP2 system makes it an ideal therapeutic target for central retinal vein occlusion (CRVO).

A Novel Therapeutic Target for Retinal Vein Occlusion  Technology Networks

A clot in the retinal vein can lead to severe and irreversible loss of vision. In a report in the American Journal of Pathology investigators utilize a newly developed ...

Global Retinal Vein Occlusion Market Chain Analysis 2019: Global Market Studies, Surveys, Outlook, Trends Analysis and Forecast2025  reportsherald.com

Global Retinal Vein Occlusion Market – Epidemiology Forecast to 2028 report delivers an in-depth understanding of the disease, historical & forecasted ...

Retinal Vein Occlusion Therapeutics – Growing Popularity and Emerging Trends in the Market 2019 – Page 31721  TheTokenClock

HTF MI released a new market study on Global Retinal Vein Occlusion Therapeutics Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread ...

Retinal Vein Occlusion Therapeutics Market with Geographical Data, Capacity, Future Prospects, Economic Aspect and forecast to 2024  The Spring Times

Retinal Vein Occlusion Therapeutics market research report 2015-2024 report portrays definition, an investigation of significant improvements in the market, ...

Global Retinal Vein Occlusion Therapeutics Market 2018-2025: Top Companies, Trends and Growth Factors, Global Market Status, Driving Factor Analysis, Competition Status  TOP Tribune

The Retinal Vein Occlusion Therapeutics Market report provide the complete analysis of Retinal Vein Occlusion Therapeutics Market Size Data and ...

Clearside's retinal vein occlusion therapy fails to meet phase 3 endpoint  Healio

Xipere, an investigational treatment for retinal vein occlusion, did not achieve its phase 3 clinical trial primary endpoint, Clearside Biomedical announced in a ...

Regeneron Pharmaceuticals, Inc. - Consenus Indicates Potential 2.9% Upside  DirectorsTalk Interviews

Regeneron Pharmaceuticals, Inc. with ticker code (REGN) have now 22 analysts in total covering the stock. The consensus rating is 'Buy'. The target price.

SCORE2 subanalysis: Visual gains made after treatment switch  Healio

WAIKOLOA, Hawaii — Visual acuity letter score and central subfield thickness both improved in eyes treated with aflibercept after a poor response to ...

Kodiak Sciences Announces Upcoming Presentation of KSI-301 12-Week Phase 1a Study Data at Angiogenesis, Exudation, and Degeneration 2019 Meeting  PRNewswire

PALO ALTO, Calif., Feb. 8, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel ...

CIBC Private Wealth Group LLC Has $2.02 Million Position in Regeneron Pharmaceuticals Inc (REGN)  Fairfield Current

CIBC Private Wealth Group LLC decreased its holdings in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 20.6% in the fourth quarter, according to the ...

Regeneron (REGN) to Report Q4 Earnings: Is a Beat in Store?  Nasdaq

Regeneron Pharmaceuticals, Inc . REGN is likely to beat expectations when it releases fourth-quarter and full year 2018 results on Feb 6, before the.

CF Patients at Greater Risk for Occlusions in Retinal Vessels, Case Report Suggests  Cystic Fibrosis News Today

A case report suggests that cystic fibrosis patients have a higher risk of retinal vein occlusions as a complication of their pro-inflammatory status.

Retinal Vein Occlusion Therapeutics Market segments by Region, Manufactures, Types and Applications – Daily Updates  Daily Updates

Retinal Vein Occlusion Therapeutics- provides top manufacturers, supply chain trends, technical inventions, important developments, and upcoming policies for ...

Contrasting of PLx Pharma Inc. (PLXP) and Coherus BioSciences Inc. (NASDAQ:CHRS)  The Hi New Ulm

Both PLx Pharma Inc. (NASDAQ:PLXP) and Coherus BioSciences Inc. (NASDAQ:CHRS) are each other's competitor in the Biotechnology industry. Thus the ...

Global Retinal Vein Occlusion Therapeutics Market 2019 By leading vendors - Acucela Inc, Addmedica SAS, Formycon AG, ThromboGenics NV  Daily Seekers

Researchstore.biz recently disclosed a new report titled Global Retinal Vein Occlusion Therapeutics Market Research Report 2012-2023 which states that the ...

Brokerages Set Clearside Biomedical Inc (CLSD) Target Price at $11.83  Fairfield Current

Shares of Clearside Biomedical Inc (NASDAQ:CLSD) have been assigned an average recommendation of “Hold” from the eleven brokerages that are presently ...

One-Year Results from Positive Phase 3 EYLEA Trial in Diabetic Retinopathy Presented at Angiogenesis Symposium  PRNewswire

TARRYTOWN, N.Y., Feb. 9, 2019 /PRNewswire/ -- Trial showed that early intervention with EYLEA improved diabetic retinopathy severity and prevented serious.

Specialist shares key messages of Euretina guidelines for management of RVO  Healio

VIENNA — A thorough ocular examination, early treatment and a timely switch of nonresponders are key for successful management of retinal vein occlusion, ...

Effect of intravitreal ranibizumab on serous retinal detachment in bra | OPTH  Dove Medical Press

Effect of intravitreal ranibizumab on serous retinal detachment in branch retinal vein occlusion Emine Dogan,1 Ozkan Sever,2 Burcin Köklü Çakir,1 Erkan Celik1 ...

Global Retinal Vein Occlusion Treatment Market 2019-2023| Strong Pipeline and Recent Drug Approvals to Boost Demand | Technavio  Business Wire

The global retinal vein occlusion treatment market 2019-2023 is expected to post a CAGR of over 9% during the forecast period, according to Technavio.

Retinal Vein Occlusion Market Rising Demand Seen in Healthcare at a CAGR of 11.2% by 2023 | By Types Branch Retinal Artery Occlusion, Central Retinal Vein Occlusion – Says MRFR |  Medgadget

Market Research Future published a research report on “Global Retinal Vein Occlusion Market” to track and analyses developments which are competitive in.

Anti-VEGF treatment of macular edema associated with retinal vein occl | OPTH  Dove Medical Press

Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in clinical practice (ECHO study report 2) J ...

Worldwide Placenta Growth Factor Market Study for 2018 to 2023 providing information of Top Companies, Trends, Growth Factors and Industry challenges of Top 20 Countries Data  K N Hearld

Global Placenta Growth Factor Market Report speaks about the growth rate of Placenta Growth Factor market till Forecast 2023, Manufacturing process, Key ...

Research Analysts Offer Predictions for Regeneron Pharmaceuticals Inc’s Q2 2019 Earnings (REGN)  Fairfield Current

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) – Analysts at Jefferies Financial Group issued their Q2 2019 earnings per share estimates for Regeneron ...

Morphological Implications of Vascular Structures Not Visualized on Optical Coherence Tomography Angiography in Retinal Vein Occlusion  Healio

Ophthalmic Surgery, Lasers and Imaging Retina | BACKGROUND AND OBJECTIVE:Advanced retinal imaging can improve understanding of retinal vein ...

Global Retinal Vein Occlusion Treatment Market 2022 Analysis by Top Vendors, Regions, Revenue, Current Status, Opportunities  News Blog

Global Retinal Vein Occlusion Treatment Market report provide provides vendors, geographical regions, annual growth rate, opportunities, driving factors, ...

Biotechnology Companies See Growth in Optic Treatment Sectors  PRNewswire

NEW YORK, Feb. 6, 2019 /PRNewswire/ -- The vast number of people in need of medical treatment has grown tremendously over the years. Some cases are a ...

Comparing of Regeneron Pharmaceuticals Inc. (REGN) and Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE)  The FinExaminer

As Biotechnology businesses, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE), are affected by compare ...

Ophthalmic Suspension Market Expected To Witness A Sustainable Growth Over 2025 By Novartis, ALLERGAN, Pfizer, Merck, Valeant Pharmaceuticals, Bayer, Genentech, Falcon Group, Ciron Drugs And Pharmaceuticals Private Limited And others  Wise Awareness

Global Ophthalmic Suspension Market Study incorporates the showcase modules ' improvement conditions and definition. The worldwide advertise is classified ...

Canada Pension Plan Investment Board Purchased 41449 Shares of Regeneron Pharmaceuticals Inc (REGN)  BharataPress

Canada Pension Plan Investment Board lifted its stake in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 39.2% in the fourth quarter, according ...

Opiant Pharmaceuticals Inc. (OPNT) and OHR Pharmaceutical Inc. (NASDAQ:OHRP) Comparison side by side  The Hi New Ulm

Opiant Pharmaceuticals Inc. (NASDAQ:OPNT) and OHR Pharmaceutical Inc. (NASDAQ:OHRP) have been rivals in the Biotechnology for quite some time.

Ozurdex for retinal vein occlusion available in China  Healio

Ozurdex is now available in China for the treatment of adult patients with macular edema secondary to retinal vein occlusion, Allergan announced in a press ...

Reviewing ProQR Therapeutics NV (PRQR)'s and Clearside Biomedical Inc. (NASDAQ:CLSD)'s results  The Hi New Ulm

Both ProQR Therapeutics N.V. (NASDAQ:PRQR) and Clearside Biomedical Inc. (NASDAQ:CLSD) are each other's competitor in the Biotechnology industry.

Global Ophthalmic Drugs Market Expected to Quadruple Registering over 6% CAGR from 2017 – 2023; Foretells MRFR Unleashing the Forecast up to 2023 - Press Release  Digital Journal

"Ophthalmic Drugs Market"Market Research Future (MRFR) has announced a new release on the global Ophthalmic Drugs market. The report takes into ...

Regeneron Pharmaceuticals (REGN) Stock Rating Reaffirmed by Cowen  Fairfield Current

Cowen reaffirmed their hold rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research note published on Monday, January 7th. Cowen ...

uniQure NV (QURE)'s Financial Results Comparing With Clearside Biomedical Inc. (NASDAQ:CLSD)  The Hi New Ulm

uniQure N.V. (NASDAQ:QURE) and Clearside Biomedical Inc. (NASDAQ:CLSD) have been rivals in the Biotechnology for quite some time. Below is a review of ...

Cystoids Macular Edema Market Segmented By Diagnosis, Therapy And Geography During 2017-2025  openPR

MarketResearchReports.Biz is providing you Retail Market Research report of "Cystoid Macular Edema Market - Global Industry Trend Analysis 2012 to 2017 ...

Contrasting of Proteostasis Therapeutics Inc. (PTI) and OHR Pharmaceutical Inc. (NASDAQ:OHRP)  The Hi New Ulm

We are contrasting Proteostasis Therapeutics Inc. (NASDAQ:PTI) and OHR Pharmaceutical Inc. (NASDAQ:OHRP) on their analyst recommendations, profitability ...

Global Retinal Vein Occlusion Therapeutics Market Overview 2019-2025 by Manufacturers: Sanofi Aventis, Valeant Pharmaceuticals, Allergan  Industry News Source

Global Retinal Vein Occlusion Therapeutics Market Research Report evaluate worldwide market product categories, regions, with sales, Retinal Vein Occlusion ...

Regeneron Pharmaceuticals Inc. (REGN) and Cue Biopharma Inc. (NASDAQ:CUE) Contrasting side by side  Thе Mоnіtоr

Since Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Cue Biopharma Inc. (NASDAQ:CUE) are part of the Biotechnology industry, they are influenced ...

Brainstorm Cell Therapeutics Inc. (BCLI)'s Financial Results Comparing With OHR Pharmaceutical Inc. (NASDAQ:OHRP)  The Hi New Ulm

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) and OHR Pharmaceutical Inc. (NASDAQ:OHRP) have been rivals in the Biotechnology for quite some time.

Regeneron Pharmaceuticals (REGN) Scheduled to Post Quarterly Earnings on Wednesday  Fairfield Current

Regeneron Pharmaceuticals (NASDAQ:REGN) will be issuing its quarterly earnings data before the market opens on Wednesday, February 6th. Analysts expect ...

Retinal Vein Occlusion Market Size and Trend by Branch and Central Retinal Vein Occlusion Type, Etc. Types and Forecast to 2023 |  Medgadget

Glaucoma is a condition where the eye pressure causes damage to the optic nerve. The increasing number of patients with glaucoma is leading the retinal vein ...

Regeneron Pharmaceuticals (REGN) Raised to Buy at Guggenheim  Fairfield Current

Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by equities research analysts at Guggenheim from a “neutral” rating to a “buy” rating in a research ...

Global Widefield Imaging Systems Market Rising Trend Including Key Players Profile like Clarity Medical Systems, Inc., Heidelberg Engineering, Visunex Medical Systems, Inc., CENTERVUE SPA, Optos - Press Release  Digital Journal

"Global Widefield Imaging Systems market"A bird's eye view of the Widefield Imaging Systems Industry made available in the report helps readers to understand ...

Post-marketing surveillance study of the safety of dexamethasone intra | OPTH  Dove Medical Press

Post-marketing surveillance study of the safety of dexamethasone intravitreal implant in patients with retinal vein occlusion or noninfectious posterior segment ...

Tonix Pharmaceuticals Holding Corp. (TNXP)'s Financial Results Comparing With Clearside Biomedical Inc. (NASDAQ:CLSD)  The FinHeadLines

This is therefore a comparing of the dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership in Tonix.

Reviewing Clearside Biomedical Inc. (CLSD)'s and Arbutus Biopharma Corporation (NASDAQ:ABUS)'s results  The FinHeadLines

Clearside Biomedical Inc. (NASDAQ:CLSD) and Arbutus Biopharma Corporation (NASDAQ:ABUS) compete with each other in the Biotechnology sector. We will ...

Reviewing BiondVax Pharmaceuticals Ltd. (BVXV)'s and OHR Pharmaceutical Inc. (NASDAQ:OHRP)'s results  The Hi New Ulm

This is a contrast between BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) and OHR Pharmaceutical Inc. (NASDAQ:OHRP) based on their institutional ...

Ocular Diagnostic Agents Market to Register a Stout Growth by End 2026 - Press Release  Digital Journal

This press release was orginally distributed by SBWire. Albany, NY -- (SBWIRE) -- 02/15/2019 -- Eye is the most accessible organ in the human body. Due to this ...

IOP spikes more likely after treatment in certain patients  Healio

Mild to moderate IOP spikes were seen after multiple injections of Ozurdex for treatment of uveitis, diabetic macular edema and retinal vein occlusion, but ...

Comparison of Bellicum Pharmaceuticals Inc. (BLCM) and OHR Pharmaceutical Inc. (NASDAQ:OHRP)  The Hi New Ulm

This is therefore a contrasting of the risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation in Bellicum.

Eyes on New York Awards to Honor Regeneron for Innovation  Invision Mag

(PRESS RELEASE) NEW YORK – Regeneron, a biotechnology company, will receive the 2019 Eyes on Innovation Award during the 16th annual Eyes on New ...

Retinal Vein Occlusion Market 2018 Highlights | By Types – Branch Retinal Artery Occlusion, Central Retinal Vein Occlusion | Top 10 Player Analysis by 2023 - Press Release  Digital Journal

Retinal Vein Occlusion Market Information: By Condition (Non-Ischemic and Ischemic), Diagnosis (Optical Coherence Tomography), Treatment and End-User ...

Avastin as effective as Eylea for treating central retinal vein occlusion  EurekAlert

Monthly eye injections of Avastin (bevacizumab) are as effective as the more expensive drug Eylea (aflibercept) for the treatment of central retinal vein occlusion ...

Retinal Vein Occlusion: H1 2018 Pipeline Review Report - ResearchAndMarkets.com  Business Wire

DUBLIN--(BUSINESS WIRE)--The "Retinal Vein Occlusion - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering. “Retinal ...

Central Retinal Vein Occlusion (CRVO)  News-Medical.net

Central retinal vein occlusion (CRVO) is the most common disease of the retinal vessels. It refers to a blockage of the vein draining the retinal tissue at the back ...

Dr. Mali's top 5 stories in ophthalmology for 2018  Ophthalmology Times

It's that time of the year again when I reflect on such an exciting and dynamic year in ophthalmology! Here are my top 5 most significant stories in ophthalmology ...

Surgical eye robot performs precision injection in patient with retinal vein occlusion  Medical Xpress

Eye surgeons at University Hospitals Leuven have been the first to use a surgical robot to operate on a patient with retinal vein occlusion. The robot uses a ...

Reviewing Sorrento Therapeutics Inc. (SRNE)'s and Clearside Biomedical Inc. (NASDAQ:CLSD)'s results  The Hi New Ulm

Sorrento Therapeutics Inc. (NASDAQ:SRNE) and Clearside Biomedical Inc. (NASDAQ:CLSD) are two firms in the Biotechnology that compete against each ...

Ozurdex for retinal vein occlusion approved in China  Healio

The Chinese Food and Drug Administration has approved Ozurdex to treat adults with macular edema after branch retinal vein occlusion or central retinal vein ...

Clearside Biomedical Provides Update on Two Phase 3 Clinical Trials of CLS-TA in Retinal Vein Occlusion  GlobeNewswire

ALPHARETTA, Ga., March 06, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing ...

Reviewing OncoSec Medical Incorporated (ONCS)'s and Clearside Biomedical Inc. (NASDAQ:CLSD)'s results  EN Digest

We will be contrasting the differences between OncoSec Medical Incorporated (NASDAQ:ONCS) and Clearside Biomedical Inc. (NASDAQ:CLSD) as far as ...

Bevacizumab as effective as aflibercept for central retinal vein occlusion  The Pharmaceutical Journal

Bevacizumab is frequently used off-label for treating macular oedema resulting from central retinal vein occlusion (CRVO), despite a lack of supporting data.

Retinal Vein Occlusion Market 2019 Global Forecasts Analysis, Company Profiles, Competitive Landscape and Key Regions 2023 Available at Market Research Future - Press Release  Digital Journal

"Retinal Vein Occlusion Market"Market Research Future has starting late imparted another examination to its wide research portfolio, which is titled as “Retinal ...

Europe's Luxturna approval tops November retina news  Healio

The European Commission's approval of Luxturna for inherited retinal disease was the most-read retina-related article on Healio.com/OSN in November.

Surgical robot successfully removes blood clot in patient with retinal vein occlusion  Healio

Blockage from a blood clot causing retinal vein occlusion in a patient was for the first time removed with the help of a surgical robot at the University Hospitals ...

Reviewing Vascular Biogenics Ltd. (VBLT)'s and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)'s results  The Moveefy

Both Vascular Biogenics Ltd. (NASDAQ:VBLT) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) are Biotechnology companies, competing one another.

Roche reports very strong results in 2018  GlobeNewswire

Basel, 31 January 2019. Group sales increase 7% [1] at constant exchange rates and in Swiss francs. Pharmaceuticals Division sales up 7%, driven mainly by ...

Biosimilar Ranibizumab Effective in Treating RVO in a Real-World Setting  The Center for Biosimilars

In India, Razumab, manufactured by Intas Pharmaceuticals, was approved as a similar biologic to ranibizumab in 2015; the retrospective study RE-ENACT ...

Disorganization of Retinal Inner Layers Linked to Visual Acuity Prognoses  MD Magazine

A new study suggests patients with disorganized retinal inner layers see lesser levels of visual acuity improvement after therapy.

Noninvasive, High-Resolution Functional Macular Imaging in Subjects With Retinal Vein Occlusion  Healio

Ophthalmic Surgery, Lasers and Imaging Retina | BACKGROUND AND OBJECTIVES:Several imaging modalities have been developed to characterize ...

Arteriovenous malformation of the iris  The BMJ

BMJ 2018; 362 doi: https://doi.org/10.1136/bmj.k3699 (Published 20 September 2018) Cite this as: BMJ 2018;362:k3699. Article; Related *content*; Metrics ...

Incyte Corporation (INCY)'s Financial Results Comparing With OHR Pharmaceutical Inc. (NASDAQ:OHRP)  The Hi New Ulm

Both Incyte Corporation (NASDAQ:INCY) and OHR Pharmaceutical Inc. (NASDAQ:OHRP) are Biotechnology companies, competing one another. We will ...

ValuEngine Lowers Clearside Biomedical (NASDAQ:CLSD) to Hold  Fairfield Current

ValuEngine cut shares of Clearside Biomedical (NASDAQ:CLSD) from a buy rating to a hold rating in a research report report published on Thursday, January ...

Easier treatment for blinding eye disease shows promise in clinical trial  Science Daily

A new study shows that an implantable delivery system for a widely used medication to treat a blinding eye disease has enabled some patients to go 15 months ...

Retinal Vein Occlusion Associated With Stroke  Medscape

Retinal vein occlusion (RVO) is significantly associated with stroke development, according to a recent study. Although the investigators adjusted for potential ...

Reviewing Osmotica Pharmaceuticals plc (OSMT)'s and OHR Pharmaceutical Inc. (NASDAQ:OHRP)'s results  The FinHeadLines

Osmotica Pharmaceuticals plc (NASDAQ:OSMT) and OHR Pharmaceutical Inc. (NASDAQ:OHRP), both competing one another are Biotechnology companies.

Biosimilars for bevacizumab and ranibizumab show promise for retinal diseases  Healio

VANCOUVER, British Columbia — Data for two new biosimilars for ranibizumab and bevacizumab, currently available in India, show the treatments are safe and ...

Steven Yeh, MD: The Promise of Suprachoroidal Injections  MD Magazine

The director of the Section of Uveitis and Vasculitis at Emory University spoke about the potential of this novel delivery method in conditions such as uveitis and ...

High systolic BP affects your retina and may lead to complete vision loss  Economic Times

Constant fluctuations in the systolic pressure can lead to many major eye complications.

Reviewing OHR Pharmaceutical Inc. (OHRP)'s and AmpliPhi Biosciences Corporation (NYSEAMERICAN:APHB)'s results  The FinHeadLines

Both OHR Pharmaceutical Inc. (NASDAQ:OHRP) and AmpliPhi Biosciences Corporation (NYSEAMERICAN:APHB) are Biotechnology companies, competing ...

Bitauto Holdings Limited (BITA) EPS Estimated At $0.24; Ohr Pharmaceutical (OHRP) Shorts Decreased By 5.19%  Port Courier

Analysts expect Bitauto Holdings Limited (NYSE:BITA) to report $0.24 EPS on March, 21.They anticipate $1.76 EPS change or 115.79% from last quarter's ...

IND application accepted for Aerie's AR-1105  Healio

The FDA has accepted an investigational new drug application for AR-1105, a treatment candidate for macular edema due to retinal vein occlusion, Aerie ...

Contrasting of OHR Pharmaceutical Inc. (OHRP) and Pacific Biosciences of California Inc. (NASDAQ:PACB)  Lives Advice

OHR Pharmaceutical Inc. (NASDAQ:OHRP) and Pacific Biosciences of California Inc. (NASDAQ:PACB) have been rivals in the Biotechnology for quite some ...

Biosimilars Reported Safe, Effective for Retinal Disease  Medscape

CHICAGO — Biosimilars made in India are as safe and effective for retinal vascular diseases as the American-made originator drugs, but cost about 40% less, ...

OHR Pharmaceutical Inc. (OHRP) and Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) Contrasting side by side  Lives Advice

Both OHR Pharmaceutical Inc. (NASDAQ:OHRP) and Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) compete on a level playing field in the Biotechnology ...

Anti-VEGF Therapy Before Steroids for Retinal Vein Occlusion  Medscape

NICE, France — Aflibercept and ranibizumab are safer than dexamethasone intravitreal implants for the treatment of central retinal vein occlusion, a new study ...

Reviewing Dynavax Technologies Corporation (DVAX)'s and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)'s results  Thе Mоnіtоr

Dynavax Technologies Corporation (NASDAQ:DVAX) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) have been rivals in the Biotechnology for quite ...

Complications After Intravitreal Injection Aggravate  Medscape

VANCOUVER, Canada — Clusters of inflammatory responses after intravitreal injections have unnerved some specialists, who will share their experiences and ...

Eylea Competition Coming But Pipeline Could Maintain Growth For Regeneron  Seeking Alpha

Eylea represents a significant portion of revenue and will face upcoming competition, which could slow Regeneron sales growth over the coming years.

» Load more